The National Eye Institute (NEI) awarded a $785,380 Cooperative Agreement grant under the Vision Research program (CFDA 93.867) to Nanoscope Technologies LLC, a for-profit limited liability company, to develop a non-invasive "sonogenetic" therapy for restoring vision in patients with retinitis pigmentosa. The project aims to utilize ultrasound stimulation of engineered mechanosensitive channels expressed in retinal ganglion cells to achieve vision restoration in animal models of retinal degeneration. Key objectives include in-vitro assessment of engineered mechanosensitive channel efficacy, in-vivo evaluation of low-power ultrasound stimulation, and sonogenetic restoration of vision in a rabbit model of retinitis pigmentosa. The 4-year project, which commenced on May 1, 2024, represents Nanoscope Technologies' continued work in advancing innovative ophthalmology therapies under the NEI's Vision Research program.
Generated 3/4/25, 7:03 AM